XML 73 R62.htm IDEA: XBRL DOCUMENT
v3.26.1

Subsequent Events (Details) - Roots Pharmaceutical - Subsequent Event - Collaborative Arrangement, Transaction with Party to Collaborative Arrangement $ in Millions | Jul. 10, 2026 USD ($)
--- | ---
Subsequent Events |
Collaborative arrangement, rights and obligations, maximum aggregate milestone payments, per product | $ 4.0
Collaborative arrangement contingent payment consideration to be received amount | $ 255.0
Collaborative arrangement contingent payment consideration to be percentage | 22.00%
Collaboration and license agreement, option to terminate days | 90 days

X
- Definition Collaboration and License Agreement, Option to Terminate, Days + References No definition available. + Details
Name: | ocgn_CollaborationAndLicenseAgreementOptionToTerminateDays
Namespace Prefix: | ocgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Maximum Aggregate Milestone Payments + References No definition available. + Details
Name: | ocgn_CollaborativeArrangementMaximumAggregateMilestonePayments
Namespace Prefix: | ocgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Collaborative Arrangement, Royalties To Be Received, Percentage Of Net Sales + References No definition available. + Details
Name: | ocgn_CollaborativeArrangementRoyaltiesToBeReceivedPercentageOfNetSales
Namespace Prefix: | ocgn_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Upfront License Fees And Near-Term Development Milestones + References No definition available. + Details
Name: | ocgn_CollaborativeArrangementUpfrontLicenseFeesAndNearTermDevelopmentMilestones
Namespace Prefix: | ocgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 855 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2 + Details
Name: | us-gaap_SubsequentEventLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ocgn_RootsPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |